Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

doi:10.1200/JCO.2010.30.1366

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Apr 2011

Hutchins Gordon, Southward Katie, Handley Kelly, Magill Laura, Beaumont Claire, Stahlschmidt Jens, Richman Susan, Chambers Philip, Seymour Matthew, Kerr David, Gray Richard, Quirke Philip

Abstract excerpt

PURPOSE: It is uncertain whether modest benefits from adjuvant chemotherapy in stage II colorectal cancer justify the toxicity, cost, and inconvenience. We investigated the usefulness of defective mismatch repair (dMMR), BRAF, and KRAS mutations in predicting tumor recurrence and sensitivity to chemotherapy. PATIENTS AND METHODS: Immunohistochemistry for dMMR and pyrosequencing for KRAS/BRAF were performed for...

Topics

Adaptor Proteins, Signal Transducing
Antineoplastic Combined Chemotherapy Protocols
Chemotherapy, Adjuvant
Colorectal Neoplasms
DNA Mismatch Repair
DNA Mutational Analysis
England
Fluorouracil

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Humans

Immunohistochemistry

Leucovorin

MutL Protein Homolog 1

MutS Homolog 2 Protein

Mutation

Neoplasm Staging

Nuclear Proteins

Odds Ratio

Patient Selection

Source

Open in PubMed

Identifiers

PMID: 21383284
DOI: 10.1200/JCO.2010.30.1366

Genes

KRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-21383284-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.PMID 21383284Read ↗

Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.Semantic proximity Read ↗

Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.Semantic proximity Read ↗

Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.Semantic proximity Read ↗

Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial‐to‐mesenchymal transitionSemantic proximity Read ↗

Impact of BRAF Gene Mutation in Nonmetastatic Colorectal Cancer on Disease Progression and Survival Outcomes.Semantic proximity Read ↗

DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics.Semantic proximity Read ↗

Population-based Screening for BRAF V600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis.Semantic proximity Read ↗

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.Semantic proximity Read ↗

Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis.Semantic proximity Read ↗

Prognostic value of Lynch syndrome, BRAFV600E , and RAS mutational status in dMMR/MSI-H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts.Semantic proximity Read ↗

The Prognostic Utilities of DNA Mismatch Repair Status and KRAS and BRAF Mutation in Korean Colorectal Cancer Patients: The KASID Multicenter Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.